Serhat Hızal
Serhat Hızal has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Kenan Şimşek
Department of Neurosurgery, Zonguldak Atatürk State Hospital, Zonguldak, Turkey
7 shared publications - Mustafa Tufan Pehlivan
Department of Neurosurgery, Buca Seyfi Demirsoy Training and Research Hospital, İzmir, Türkiye
6 shared publications - Mustafa Tufan Pehlivan
Department of Neurosurgery, Buca Seyfi Demirsoy Eğitim ve Araştırma Hastanesi, Izmir, Turkey
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 62 (1) , 169
Surgical versus conservative management of traumatic acute subdural haematoma in older adults: a systematic review and qualitative synthesis in the RESCUE-ASDH era
Background: Evidence guiding surgery versus conservative care for traumatic acute subdural haematoma (ASDH) in older adults is heterogeneous and vulnerable to treatment-selection bias. We systematically reviewed contemporary elderly-focused evidence and interpreted major all-age comparative studies as indirect evidence. Methods: PRISMA 2020 was followed. PubMed/MEDLINE was searched from 1 January 2020 to 27 August 2026 for traumatic ASDH studies reporting mortality, functional outcome, treatment escalation or complications in populations aged ≥ 60 years, separable elderly subgroups, or explicitly elderly cohorts. Two reviewers were designated to screen, extract data and assess risk of bias. ROBINS-I/JBI tools and GRADE principles informed appraisal. Because of clinical heterogeneity, overlapping cohorts and confounding by indication, synthesis was qualitative and no pooled effect estimate was calculated. Results: The search identified 126 records; 49 full-text reports were assessed and 21 reports describing 19 distinct elderly-focused cohorts were included. No completed randomised trial specifically compared surgery with conservative care in older adults. Comparative cohorts produced inconsistent mortality findings and no reproducible functional-outcome advantage for routine surgery; the certainty of this evidence was very low. Craniotomy-versus-craniectomy observations in elderly subgroups were strongly confounded by severity, while the all-age RESCUE-ASDH trial found similar functional outcomes between procedures. Limited craniotomy, endoscopic evacuation and delayed burr-hole strategies were feasible only in highly selected, neurologically stable patients. Admission GCS, pupillary response and midline shift were consistent prognostic variables; frailty was promising but insufficiently validated as a treatment-effect modifier. Conclusions: Current evidence does not support a general claim that surgery improves survival or functional recovery across all older adults with traumatic ASDH. Surgery remains standard for unequivocal neurological deterioration or mass effect, but when genuine clinical equipoise exists, monitored initial conservative care may be reasonable. If evacuation is required and the bone flap can safely be replaced, craniotomy is a reasonable default; decompressive craniectomy should be guided by intraoperative swelling rather than age alone. These conclusions are limited by very low-certainty observational evidence.
- 10 September 2026
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 62 (1) , 169
Open AccessSurgical versus conservative management of traumatic acute subdural haematoma in older adults: a systematic review and qualitative synthesis in the RESCUE-ASDH era
Background: Evidence guiding surgery versus conservative care for traumatic acute subdural haematoma (ASDH) in older adults is heterogeneous and vulnerable to treatment-selection bias. We systematically reviewed contemporary elderly-focused evidence and interpreted major all-age comparative studies as indirect evidence. Methods: PRISMA 2020 was followed. PubMed/MEDLINE was searched from 1 January 2020 to 27 August 2026 for traumatic ASDH studies reporting mortality, functional outcome, treatment escalation or complications in populations aged ≥ 60 years, separable elderly subgroups, or explicitly elderly cohorts. Two reviewers were designated to screen, extract data and assess risk of bias. ROBINS-I/JBI tools and GRADE principles informed appraisal. Because of clinical heterogeneity, overlapping cohorts and confounding by indication, synthesis was qualitative and no pooled effect estimate was calculated. Results: The search identified 126 records; 49 full-text reports were assessed and 21 reports describing 19 distinct elderly-focused cohorts were included. No completed randomised trial specifically compared surgery with conservative care in older adults. Comparative cohorts produced inconsistent mortality findings and no reproducible functional-outcome advantage for routine surgery; the certainty of this evidence was very low. Craniotomy-versus-craniectomy observations in elderly subgroups were strongly confounded by severity, while the all-age RESCUE-ASDH trial found similar functional outcomes between procedures. Limited craniotomy, endoscopic evacuation and delayed burr-hole strategies were feasible only in highly selected, neurologically stable patients. Admission GCS, pupillary response and midline shift were consistent prognostic variables; frailty was promising but insufficiently validated as a treatment-effect modifier. Conclusions: Current evidence does not support a general claim that surgery improves survival or functional recovery across all older adults with traumatic ASDH. Surgery remains standard for unequivocal neurological deterioration or mass effect, but when genuine clinical equipoise exists, monitored initial conservative care may be reasonable. If evacuation is required and the bone flap can safely be replaced, craniotomy is a reasonable default; decompressive craniectomy should be guided by intraoperative swelling rather than age alone. These conclusions are limited by very low-certainty observational evidence.
- 24 July 2026
- Published by IGI Global Scientific Publishing
- p. 297-328
AI-Powered Patient Education and Triage Tools in Community Neurosurgery
AI in neurosurgery has been largely described from the perspective of well-resourced academic centers. Yet most of the global neurosurgical workforce practices in community and state hospitals without institutional data-science infrastructure. This chapter presents an implementation case study of an AI-integrated platform designed, built, and deployed by a practicing neurosurgeon at a Turkish state hospital, with cross-institutional analysis from co-authors at two Turkish settings. The system combines an LLM chatbot configured for Turkish-language neurosurgical queries, 48 interactive patient-facing tools, a rule-based treatment-decision interface for lumbar and cervical disc pathology, and automated content-generation pipelines. The authors describe system architecture, linguistic adaptation, ethical considerations under KVKK, cost structure, and implementation lessons.
- 24 July 2026
- Published by IGI Global Scientific Publishing
- p. 297-328
AI-Powered Patient Education and Triage Tools in Community Neurosurgery
AI in neurosurgery has been largely described from the perspective of well-resourced academic centers. Yet most of the global neurosurgical workforce practices in community and state hospitals without institutional data-science infrastructure. This chapter presents an implementation case study of an AI-integrated platform designed, built, and deployed by a practicing neurosurgeon at a Turkish state hospital, with cross-institutional analysis from co-authors at two Turkish settings. The system combines an LLM chatbot configured for Turkish-language neurosurgical queries, 48 interactive patient-facing tools, a rule-based treatment-decision interface for lumbar and cervical disc pathology, and automated content-generation pipelines. The authors describe system architecture, linguistic adaptation, ethical considerations under KVKK, cost structure, and implementation lessons.
- Open Access
- 8 July 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 115
Intrawound vancomycin powder for the prevention of surgical site infection in cranial neurosurgery: a narrative review
Background: Surgical site infections (SSIs) following cranial neurosurgical procedures contribute to significant morbidity, prolonged hospitalisation and healthcare expenditure. Intrawound vancomycin powder (IVP), extensively investigated in spinal surgery, has been increasingly applied as a prophylactic adjunct in cranial neurosurgery. However, the supporting evidence is methodologically limited and inconsistent, comprising predominantly retrospective single-centre studies with conflicting findings across procedure types, the retraction of two influential meta-analyses in April 2025 and the recent publication of the first large randomised controlled trial (RCT)—all of which mandate a critical re-appraisal of current practice. Objective: This narrative review synthesises the current evidence regarding the efficacy, safety and clinical application of IVP for SSI prevention following cranial neurosurgery, with attention to procedure-specific outcomes, dosing considerations, controversies and knowledge gaps. Methods: A comprehensive narrative literature search was performed in PubMed/MEDLINE, Scopus and Web of Science for English-language studies published between January 2000 and March 2026 evaluating IVP use in cranial neurosurgery. Randomised trials, cohort studies, systematic reviews and meta-analyses were included and synthesised by procedure type. Results: Observational evidence has been associated with reduced SSI rates following craniotomy with IVP; however, the first adequately powered RCT, by Kannan and colleagues ( n = 1,103), demonstrated no significant difference between treatment and control groups (3.94% versus 4.10%; p = 0.90), and the suggestion of greater benefit in higher-risk subgroups is not consistently supported. Findings in cranioplasty remain markedly conflicting, with some studies reporting near-elimination of SSI and others showing no benefit. Data on deep brain stimulation (DBS) and ventriculoperitoneal (VP) shunt surgery are sparse and inconclusive. Reported doses range from 500 mg to 2 g, with minimal systemic absorption and a favourable safety profile. A large retrospective study of 987 nonmalignant cranial procedures further questioned routine IVP prophylaxis in low-risk populations. Conclusion: IVP is a pharmacologically rational, low-cost and generally well-tolerated adjunct that may have a role in SSI prevention in selected cranial procedures. However, the heterogeneity of evidence, the negative first RCT and the absence of adequately powered confirmatory trials preclude universal adoption. A risk-stratified, procedure-specific approach is prudent until more robust evidence emerges.
- 8 July 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 115
Open AccessIntrawound vancomycin powder for the prevention of surgical site infection in cranial neurosurgery: a narrative review
Background: Surgical site infections (SSIs) following cranial neurosurgical procedures contribute to significant morbidity, prolonged hospitalisation and healthcare expenditure. Intrawound vancomycin powder (IVP), extensively investigated in spinal surgery, has been increasingly applied as a prophylactic adjunct in cranial neurosurgery. However, the supporting evidence is methodologically limited and inconsistent, comprising predominantly retrospective single-centre studies with conflicting findings across procedure types, the retraction of two influential meta-analyses in April 2025 and the recent publication of the first large randomised controlled trial (RCT)—all of which mandate a critical re-appraisal of current practice. Objective: This narrative review synthesises the current evidence regarding the efficacy, safety and clinical application of IVP for SSI prevention following cranial neurosurgery, with attention to procedure-specific outcomes, dosing considerations, controversies and knowledge gaps. Methods: A comprehensive narrative literature search was performed in PubMed/MEDLINE, Scopus and Web of Science for English-language studies published between January 2000 and March 2026 evaluating IVP use in cranial neurosurgery. Randomised trials, cohort studies, systematic reviews and meta-analyses were included and synthesised by procedure type. Results: Observational evidence has been associated with reduced SSI rates following craniotomy with IVP; however, the first adequately powered RCT, by Kannan and colleagues ( n = 1,103), demonstrated no significant difference between treatment and control groups (3.94% versus 4.10%; p = 0.90), and the suggestion of greater benefit in higher-risk subgroups is not consistently supported. Findings in cranioplasty remain markedly conflicting, with some studies reporting near-elimination of SSI and others showing no benefit. Data on deep brain stimulation (DBS) and ventriculoperitoneal (VP) shunt surgery are sparse and inconclusive. Reported doses range from 500 mg to 2 g, with minimal systemic absorption and a favourable safety profile. A large retrospective study of 987 nonmalignant cranial procedures further questioned routine IVP prophylaxis in low-risk populations. Conclusion: IVP is a pharmacologically rational, low-cost and generally well-tolerated adjunct that may have a role in SSI prevention in selected cranial procedures. However, the heterogeneity of evidence, the negative first RCT and the absence of adequately powered confirmatory trials preclude universal adoption. A risk-stratified, procedure-specific approach is prudent until more robust evidence emerges.
- 15 June 2026
- Published by Taylor & Francis in British Journal Of Neurosurgery
- p. 1-3
Early lumbar microdiscectomy and quality-of-life outcomes: methodological considerations regarding the pilot study by Horan et al.
Horan and colleagues recently reported a pilot study examining quality-of-life outcomes following early versus late elective lumbar microdiscectomy, concluding that surgery within twelve months is associated with superior patient-reported outcomes and proposing a six-month maximum waiting time. While the clinical question is both relevant and timely, we believe several methodological and conceptual issues merit discussion before such a recommendation is translated into practice. First, the study conflates waitlist time with symptom duration, yet its Discussion and proposed threshold are predominantly grounded in literature examining the latter. Second, only 38 of 64 eligible patients (59%) were included in the analysis, with no characterisation of non-responders, and the postoperative assessment window varied from ten to thirty-four months, introducing substantial noise into between-group comparisons. Third, the absence of preoperative baseline scores precludes calculation of minimal clinically important differences and leaves the authors' conclusions vulnerable to baseline imbalance. Fourth, the authors' own data reveal a cost and complication paradox: the early group experienced a longer length of stay, a higher median cost, and a ten per cent cerebrospinal-fluid leak rate versus zero per cent in the late group-findings that directly oppose the cost-consequence literature invoked in support of their thesis. Finally, the study period coincided with the COVID-19 pandemic, which substantially altered surgical throughput and perioperative pathways across Europe; this temporal confounding is neither acknowledged nor adjusted for. A robust answer to this important question will require a prospective design with capture of symptom duration, preoperative and standardised-interval postoperative outcome measures, an a priori sample-size calculation, formal characterisation of non-responders, and adjustment for era-related confounders.
- 15 June 2026
- Published by Taylor & Francis in British Journal Of Neurosurgery
- p. 1-3
Early lumbar microdiscectomy and quality-of-life outcomes: methodological considerations regarding the pilot study by Horan et al.
Horan and colleagues recently reported a pilot study examining quality-of-life outcomes following early versus late elective lumbar microdiscectomy, concluding that surgery within twelve months is associated with superior patient-reported outcomes and proposing a six-month maximum waiting time. While the clinical question is both relevant and timely, we believe several methodological and conceptual issues merit discussion before such a recommendation is translated into practice. First, the study conflates waitlist time with symptom duration, yet its Discussion and proposed threshold are predominantly grounded in literature examining the latter. Second, only 38 of 64 eligible patients (59%) were included in the analysis, with no characterisation of non-responders, and the postoperative assessment window varied from ten to thirty-four months, introducing substantial noise into between-group comparisons. Third, the absence of preoperative baseline scores precludes calculation of minimal clinically important differences and leaves the authors' conclusions vulnerable to baseline imbalance. Fourth, the authors' own data reveal a cost and complication paradox: the early group experienced a longer length of stay, a higher median cost, and a ten per cent cerebrospinal-fluid leak rate versus zero per cent in the late group-findings that directly oppose the cost-consequence literature invoked in support of their thesis. Finally, the study period coincided with the COVID-19 pandemic, which substantially altered surgical throughput and perioperative pathways across Europe; this temporal confounding is neither acknowledged nor adjusted for. A robust answer to this important question will require a prospective design with capture of symptom duration, preoperative and standardised-interval postoperative outcome measures, an a priori sample-size calculation, formal characterisation of non-responders, and adjustment for era-related confounders.
- 4 June 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 203, 112978
Cervical muscle morphology in women with disc herniation: methodological and interpretative considerations
- 4 June 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 203, 112978
Cervical muscle morphology in women with disc herniation: methodological and interpretative considerations
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-3
Methodological Considerations on the Retrospective Cohort Study of Remifentanil-Propofol versus Propofol Alone in Severe Traumatic Brain Injury [Letter]
Letter for the article Remifentanil-Propofol versus Propofol Alone in Patients with Severe Traumatic Brain Injury: A Retrospective Cohort Study on Anesthesia Outcomes
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-3
Open AccessMethodological Considerations on the Retrospective Cohort Study of Remifentanil-Propofol versus Propofol Alone in Severe Traumatic Brain Injury [Letter]
Letter for the article Remifentanil-Propofol versus Propofol Alone in Patients with Severe Traumatic Brain Injury: A Retrospective Cohort Study on Anesthesia Outcomes
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-4
Methodological Considerations on the Reported Association Between Postoperative Chronic Back Pain Syndrome and Psychiatric, Brain, and Mortality Outcomes in a Korean Nationwide Cohort [Letter]
Letter for the article Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality
- 1 June 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-4
Open AccessMethodological Considerations on the Reported Association Between Postoperative Chronic Back Pain Syndrome and Psychiatric, Brain, and Mortality Outcomes in a Korean Nationwide Cohort [Letter]
Letter for the article Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality